News
-
- Investor Relations
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2027 [IFRS]
-
- Investor Relations
Notice Regarding Earnings Forecast and Dividend Forecast for the Fiscal Year Ending March 31, 2027
-
- Investor Relations
Financial Results for Q1 - FY2026 & Full-Year Forecasts for FY2026
-
- Investor Relations
Notice of Resolutions Adopted at The 114th Ordinary General Meeting of Shareholders
-
- Investor Relations
Partial Corrections to “Convocation Notice of the 114th Ordinary General Meeting of Shareholders”
-
- Investor Relations
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2027 [IFRS]
-
- Investor Relations
Notice Regarding Earnings Forecast and Dividend Forecast for the Fiscal Year Ending March 31, 2027
-
- Investor Relations
Financial Results for Q1 - FY2026 & Full-Year Forecasts for FY2026
-
- Investor Relations
Notice of Resolutions Adopted at The 114th Ordinary General Meeting of Shareholders
-
- Investor Relations
Partial Corrections to “Convocation Notice of the 114th Ordinary General Meeting of Shareholders”
-
- Investor Relations
Convocation Notice of The 114th Ordinary General Meeting of Shareholders
-
- Sustainability
-
- Sustainability
-
- Sustainability
-
- Sustainability
-
- Sustainability
- Investor Relations
Nippon Shokubai Published “TechnoAmenity Report 2024,” and “Financial Report 2024.”
-
- Sustainability
- Investor Relations
-
- Research and Development
-
- Research and Development
-
- Research and Development
-
- Research and Development
-
- Research and Development
-
- Research and Development
3D Cell Culture Vessel “MicoCell™” First Application in Regenerative Medicine










